Burns Matteson Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Burns Matteson Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,512	Closed	-$575K	–	196
2026 Q1	$575K	Buy	2,512 +1,083	+76%	+$243K	0.21%	87
2025 Q4	$305K	Buy	1,429 +135	+10%	+$27.9K	0.11%	154
2025 Q3	$257K	Buy	+1,294	New	+$241K	0.1%	164

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Burns Matteson Capital Management's ASND Position: Q2 2026 in Review

Burns Matteson Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 2,512 shares — an estimated $575K sold.

Burns Matteson Capital Management first reported a position in ASND in Q3 2025 and held it in 3 quarters. The position peaked at $575K in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Burns Matteson Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Burns Matteson Capital Management sold 2,512 Ascendis Pharma A/S shares in Q2 2026, an estimated $575K.
Burns Matteson Capital Management first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 3 quarters.
Burns Matteson Capital Management's Ascendis Pharma A/S position peaked at $575K in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Burns Matteson Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.